Cyclacel pharmaceuticals reports fourth quarter and full year 2022 financial results and provides business update

- on track to start oral fadraciclib phase 2 proof of concept in 1h 2023 and report interim data in 2h 2023 -
CYCC Ratings Summary
CYCC Quant Ranking